IX BIOPHARMA LTD.

SGX: 42C (IX Biopharma)

Last update: 2 days ago, 8:24PM

0.028

0.00 (3.70%)

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (SG) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock IX Biopharma - -

Stockmoo Score

0.8

Similar Stocks

Stock Market Cap DY P/E P/B
IX BIOPHARMA 25 M - - 2.74
TJ DARENTANG USD 3 B 8.32% 12.53 1.90
PHARMESIS INTL 4 M - - 0.410

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Core

Ownership

Name Date Shares Held
Lee (Yip Hang Eddy) 19 Jul 2024 217,000,852 (24.57%)
HRT Corporation Pte. Ltd. 19 Jul 2024 66,748,029 (7.56%)
Tang (Choy Leng Jane) 19 Jul 2024 22,793,565 (2.58%)
Narulla (Jaspal Singh) 31 Aug 2023 16,989,383 (1.92%)
Tan (See Tee) 31 Aug 2023 16,555,900 (1.87%)

No data within this time range.

No data within this time range.

Date Type Details
02 Sep 2024 Announcement General Announcement::Press Release - New Study Demonstrates that SL-NAD+ Delivers NAD+ into Cells
23 Aug 2024 Announcement Financial Statements and Related Announcement::Full Yearly Results
23 Aug 2024 TheEdge iX Biopharma losses widen 12% y-o-y to $10.8 mil in FY2024
12 Aug 2024 Announcement General Announcement::Press Release - New Study Highlights CBD Wafer's Potential in Kidney Failure Patients
24 Jul 2024 Announcement Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Changes in Interest by Substantial Shareholder - Anson Properties Pte. Ltd.
24 Jul 2024 Announcement Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung
24 Jul 2024 Announcement Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Eddy Lee Yip Hang
22 Jul 2024 Announcement REPL::Rights::Voluntary
22 Jul 2024 Announcement Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung
22 Jul 2024 Announcement Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Eddy Lee Yip Hang
22 Jul 2024 Announcement REPL::General Announcement::Issue and Listing of the Rights Shares and the Warrants
19 Jul 2024 Announcement General Announcement::Issue and Listing of the Rights Shares and the Warrants
15 Jul 2024 Announcement General Announcement::Notice From Undertaking Shareholder Anson Properties Pte. Ltd.
09 Jul 2024 Announcement General Announcement::Press Release - Breakthrough Sublingual Wafers Raise NAD+ Levels, Enhance Well-Being in Human Trial
02 Jul 2024 Announcement Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung
02 Jul 2024 Announcement Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Eddy Lee Yip Hang
01 Jul 2024 Announcement General Announcement::Proposed Renounceable Non-Underwritten Rights Cum Warrants Issue: Despatch of Notification and Forms
26 Jun 2024 Announcement REPL::Rights::Voluntary
18 Jun 2024 Announcement General Announcement::Notice of Adjustment to Conversion Price of 9% Convertible Bonds Principal Amount S$2 Million
18 Jun 2024 Announcement REPL::Rights::Voluntary
11 Jun 2024 Announcement REPL::Rights::Voluntary
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria